With the average clinical trial using of 5-7 different clinical systems, one of the critical business challenges the industry faces today is turning these siloes of data into operational intelligence
"With the average clinical trial using of 5-7 different clinical systems, one of the critical business challenges the industry faces today is turning these siloes of data into operational intelligence," said Peg Regan, President & CEO of eClinical Insights. To address this issue, eClinical Insights, a provider of cloud-based clinical trials software, announced the launch of its eClinical Intelligence Platform.
The platform delivers real-time clinical trial intelligence and workflow capabilities through a suite of cloud-based applications, which acquires and integrates data from any clinical system, and is powered by a business analytics engine. The platform is based on an open architecture and includes a library of out-of-the-box interfaces to leading EDC technologies, enabling customers to leverage existing technology investments as integrated components of the eClinical Insights platform. Delivered through a Software-as-a-Service (SaaS) subscription model, the platform includes a suite of cloud-based trial management applications that are available on per study basis, and can be turned on and off as needed, on both new and ongoing trials.
You can read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III POETYK PsA Trials Show Significant Clinical Benefit with Sotyktu in Psoriatic Arthritis
June 13th 2025New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in adults with active psoriatic arthritis, maintaining efficacy through 52 weeks of treatment.